Index -
P/E 0.34
EPS (ttm) 1.28
Insider Own 52.23%
Shs Outstand 4.97M
Perf Week -6.72%
Market Cap 3.72M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 4.13M
Perf Month -29.51%
Income 3.06M
PEG -
EPS next Q -
Inst Own 4.33%
Short Float / Ratio 3.00% / 8.71
Perf Quarter -46.80%
Sales 23.79M
P/S 0.16
EPS this Y -
Inst Trans -0.96%
Short Interest 0.12M
Perf Half Y -54.26%
Book/sh 1.12
P/B 0.38
EPS next Y -
ROA 11.25%
Target Price 2.00
Perf Year -57.43%
Cash/sh 0.27
P/C 1.60
EPS next 5Y -
ROE 56.40%
52W Range 0.37 - 1.78
Perf YTD -62.61%
Dividend -
P/FCF -
EPS past 5Y 55.67%
ROI 19.01%
52W High -75.84%
Beta 1.07
Dividend % -
Quick Ratio 2.56
Sales past 5Y 1609.32%
Gross Margin 92.58%
52W Low 16.82%
ATR 0.05
Employees 13
Current Ratio 2.56
Sales Q/Q -100.00%
Oper. Margin 13.48%
RSI (14) 34.99
Volatility 12.02% 9.57%
Optionable No
Debt/Eq 0.72
EPS Q/Q 58.78%
Profit Margin 12.88%
Rel Volume 6.16
Prev Close 0.38
Shortable Yes
LT Debt/Eq 0.66
Earnings -
Payout -
Avg Volume 14.23K
Price 0.43
Recom 3.00
SMA20 -16.46%
SMA50 -29.39%
SMA200 -52.29%
Volume 86,719
Change 13.16%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-21 Downgrade
Chardan Capital Markets
Buy → Neutral
$2.25 → $0.40
Dec-18-20 Initiated
BMO Capital Markets
Outperform
$6
Nov-20-19 Initiated
Guggenheim
Buy
$9
Nov-28-23 04:01PM
Aug-23-23 09:48AM
Aug-11-23 04:01PM
Jul-14-23 04:01PM
May-26-23 04:01PM
04:01PM
Loading…
May-19-23 04:01PM
May-04-23 04:01PM
Apr-27-23 07:00AM
Mar-27-23 04:01PM
Feb-24-23 05:10PM
Dec-14-22 05:00AM
Nov-14-22 04:01PM
Sep-26-22 04:01PM
Sep-01-22 07:00AM
Aug-15-22 04:01PM
04:01PM
Loading…
Jul-20-22 04:01PM
Jun-29-22 12:00PM
May-27-22 04:01PM
May-17-22 07:00AM
May-16-22 04:01PM
May-10-22 07:21PM
May-09-22 07:00AM
Mar-25-22 04:15PM
Feb-04-22 11:25AM
(American City Business Journals)
07:00AM
Jan-05-22 01:38PM
Dec-31-21 07:07PM
06:02PM
02:53PM
01:15PM
05:57PM
Loading…
Dec-30-21 05:57PM
03:31PM
10:00AM
Dec-29-21 11:46PM
05:57PM
04:30PM
10:45AM
Dec-28-21 05:57PM
02:50PM
10:00AM
Dec-27-21 03:16PM
11:00AM
Dec-26-21 08:32AM
Dec-24-21 06:13PM
01:56PM
10:40AM
Dec-23-21 08:38PM
09:30AM
Dec-22-21 06:22PM
05:59PM
04:50PM
02:32PM
11:00AM
10:00AM
Dec-21-21 05:54PM
04:08PM
11:00AM
09:30AM
07:38AM
Dec-20-21 05:47PM
03:49PM
11:00AM
11:00AM
10:00AM
Dec-19-21 09:00PM
08:32AM
Dec-17-21 06:13PM
05:00PM
01:40PM
12:32PM
09:45AM
Dec-16-21 03:50PM
03:00PM
11:00AM
11:00AM
12:49AM
Dec-15-21 05:59PM
04:00PM
01:36PM
12:15PM
09:10AM
Dec-14-21 09:00PM
01:53PM
12:45PM
10:12AM
09:34AM
Dec-13-21 10:00PM
06:57PM
05:15PM
04:30PM
03:38PM
01:20PM
10:15AM
Dec-12-21 09:00PM
Dec-10-21 05:36PM
Dec-08-21 12:55PM
Dec-07-21 09:00PM
04:37PM
Dec-03-21 08:35PM
06:13PM
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
CBI USA, Inc. 10% Owner Dec 15 Buy 1.60 3,400,000 5,440,000 4,218,299 Dec 19 04:54 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite